MARKET

RGLS

RGLS

Regulus
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.7027
-0.0203
-2.81%
Closed 16:00 09/28 EDT
OPEN
0.7230
PREV CLOSE
0.7230
HIGH
0.7329
LOW
0.7002
VOLUME
631.89K
TURNOVER
--
52 WEEK HIGH
2.320
52 WEEK LOW
0.4500
MARKET CAP
61.16M
P/E (TTM)
-3.0539
1D
5D
1M
3M
1Y
5Y
Regulus Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
/PRNewswire/ --  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that , President and Chief Executive Officer of Regulus, will pr...
PR Newswire - PRF · 09/09 20:41
Cantor Fitzgerald Initiates Coverage On Regulus Therapeutics with Overweight Rating, Announces Price Target of $2
Cantor Fitzgerald analyst Brian Cheng initiates coverage on Regulus Therapeutics (NASDAQ:RGLS) with a Overweight rating and announces Price Target of $2.
Benzinga · 09/02 12:29
12 Health Care Stocks Moving In Tuesday's After-Market Session
 Gainers  
Benzinga · 08/17 20:41
BRIEF-Regulus Therapeutics Posts Q2 Loss Per Share Of $0.08
reuters.com · 08/10 21:48
Recap: Regulus Therapeutics Q2 Earnings
Shares of Regulus Therapeutics (NASDAQ:RGLS) fell in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 65.22% year over year to ($0.08), which were in line with the estimate of ($0.08).
Benzinga · 08/10 20:57
Regulus Therapeutics Q2 EPS $(0.08), Inline
Regulus Therapeutics (NASDAQ:RGLS) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is a 65.22 percent increase over losses of $(0.23) per share from the same period last
Benzinga · 08/10 20:57
Regulus Therapeutics Narrows Q2 Loss from Year Ago, Sees Enough Funds Till Q4 Next Year
MT Newswires · 08/10 16:36
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 9)
Benzinga · 08/10 11:55
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RGLS. Analyze the recent business situations of Regulus through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
50.00%Buy
50.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average RGLS stock price target is 1.375 with a high estimate of 2.000 and a low estimate of 0.5000.
High2.000
Average1.375
Low0.5000
Current 0.7027
EPS
Actual
Estimate
-0.17-0.13-0.08-0.04
Q3 2020
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Institutional Holdings
Institutions: 63
Institutional Holdings: 24.15M
% Owned: 27.75%
Shares Outstanding: 87.04M
TypeInstitutionsShares
Increased
13
1.52M
New
14
953.87K
Decreased
4
955.67K
Sold Out
11
5.74M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.50%
Pharmaceuticals & Medical Research
-1.90%
Key Executives
Non-Executive Chairman/Independent Director
Stelios Papadopoulos
President/Chief Executive Officer/Director
Joseph Hagan
Chief Financial Officer
Crispina Calsada
Senior Vice President/General Counsel
Christopher Aker
Chief Scientific Officer
Denis Drygin
Independent Director
David Baltimore
Independent Director
Kathryn Collier
Independent Director
Alice Huang
Independent Director
Jake Nunn
Independent Director
William Rastetter
Independent Director
Hugh Rosen
Independent Director
Simos Simeonidis
Independent Director
Pascale Witz
No Data
About RGLS
Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing drugs targeting microRNAs to treat diseases. Its product candidates are RG-012 and RGLS4326. RG-012 is an anti-miR targeting miR-21 for the treatment of Alport syndrome, a kidney disease. The Company completed Phase I multiple-ascending dose (MAD) clinical trial. RGLS4326, an anti-miR targeting miR-17, is for the treatment of autosomal dominant polycystic kidney disease (ADPKD). It is in Phase I clinical trial. The Company’s pre-clinical pipeline candidates include RGLS5579 and anti-miR-132. RGLS5579 is developing for the treatment of Glioblastoma and anti-miR-132 is developing for the treatment of non-alcoholic steatohepatitis. Its developing two undisclosed products under Cell Therapies program and Hepatitis B virus program.

Webull offers kinds of Regulus Therapeutics Inc stock information, including NASDAQ:RGLS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RGLS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RGLS stock methods without spending real money on the virtual paper trading platform.